IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

| ABBOTT CARDIOVASCULAR SYSTEMS INC. and ABBOTT LABORATORIES INC., |) |
|--|------------------------------------|
| Plaintiffs, |) |
| |) Civil Action No. 98-80 (SLR) |
| V. | (Consolidated with C.A. No. 98-314 |
| | (SLR) and C.A. No. 98-316 (SLR)) |
| MEDTRONIC VASCULAR, INC. and |) |
| MEDTRONIC USA, INC., |) |
| |) |
| Defendants. |) |

SUBMISSION OF FDA LETTER PROVIDING NOTICE OF APPROVAL OF ABBOTT'S XIENCE DRUG-ELUTING STENT

Pursuant to Local Rule 7.1.2(c), Abbott Cardiovascular Systems Inc. and Abbott
Laboratories Inc. (collectively "Abbott") submit a copy of a letter dated July 2, 2008, from the
Food and Drug Administration ("FDA"), notifying Abbott that the FDA has approved Abbott's
application to begin marketing its Xience™ V Everolimus Eluting Coronary Stent System
("Xience") in the United States. (Ex. 1.) On the same date, Abbott issued a press release
announcing its immediate release of the Xience in the United States. (Ex. 2.) Because Abbott's
Xience competes directly against Medtronic's infringing Endeavor (which contains Medtronic's
infringing Driver stent), Medtronic's infringing sales of its Endeavor have been causing
substantial irreparable harm to Abbott, particularly in light of Abbott's recent release of the
Xience in the United States.

To address Medtronic's infringing sales of its Endeavor, Abbott requests that the Court grant Abbott's Motion to Lift Stay of Proceedings on Abbott's Motion for Permanent Injunction as to Medtronic's Endeavor (D.I. 824) and enjoin Medtronic from continuing to infringe

Abbott's patents-in-suit through sales of the Endeavor and Medtronic's other infringing stents. In particular, when deciding Abbott's request for an injunction of the Endeavor, Abbott requests that the Court consider the fact that Abbott's newly released Xience competes directly against Medtronic's infringing Endeavor in the U.S. stent market.

Of Counsel:

J. Michael Jakes
Gerald F. Ivey
Michael A. Morin
FINNEGAN, HENDERSON, FARABOW
GARRETT & DUNNER, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413
(202) 408-4000

Dated: July 21, 2008

Frederick L. Cottrell, III (#2555)

cottrell@rlf.com

Anne Shea Gaza (#4093)

gaza@rlf.com

RICHARDS, LAYTON & FINGER

One Rodney Square 920 N. King Street Wilmington, Delaware 19801 (302) 651-7700

Attorneys for Plaintiffs Abbott Cardiovascular Systems Inc. and Abbott Laboratories Inc

UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE

CERTIFICATE OF SERVICE

I hereby certify that on July 21, 2008, I caused to be served by hand delivery the foregoing document and electronically filed the same with the Clerk of Court using CM/ECF which will send notification of such filing(s) to the following:

Karen Jacobs Louden, Esquire Morris, Nichols, Arsht & Tunnell 1201 N. Market Street P.O. Box 1347 Wilmington, Delaware 19899-1347

I hereby certify that on July 21, 2008, I have sent by Federal Express the foregoing document to the following non-registered participants:

Kevin S. Rosen, Esquire Matthew Hoffman, Esquire Anthony S. Newman, Esquire Gibson, Dunn & Crutcher LLP 333 South Grand Avgneue Los Angeles, CA 90071-3197 H. Mark Ryan, Esquire Frederick S. Chung, Esquire Gibson, Dunn & Crutcher LLP 1881 Page Mill Road Palo Alto, CA 94304-1211

Anne Shea Gaza (#4093)

Richards, Layton & Finger, P.A.

One Rodney Square

P.O. Box 551

Wilmington, Delaware 19899

(302) 651-7700

gaza@rlf.com